These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2463757)

  • 1. Variability in MSAFP predicted rates of Down syndrome.
    Macri JN; Krantz DA; Cook EJ; Sorensen K; Kasturi RV
    Am J Hum Genet; 1989 Feb; 44(2):296-7. PubMed ID: 2463757
    [No Abstract]   [Full Text] [Related]  

  • 2. Down syndrome and low maternal serum alpha fetoprotein.
    Jacobs S; Giles W
    Aust N Z J Obstet Gynaecol; 1990 Nov; 30(4):335-40. PubMed ID: 1707270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in predicted rates of Down syndrome associated with elevated maternal serum alpha-fetoprotein levels in older women.
    Hook EB
    Am J Hum Genet; 1988 Aug; 43(2):160-4. PubMed ID: 2456690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Maternal serum alpha-fetoprotein as a screening test for fetal Down syndrome].
    Bessho T; Kanazawa R; Shiotani T; Mitsuo M; Koyama K
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Mar; 47(3):237-43. PubMed ID: 7535328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.
    MacDonald ML; Wagner RM; Slotnick RN
    Obstet Gynecol; 1991 Jan; 77(1):63-8. PubMed ID: 1701526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two Down syndrome screening strategies for women aged 35 and older.
    Palomaki GE; Haddow JE
    Prenat Diagn; 1994 Sep; 14(9):898-9. PubMed ID: 7531329
    [No Abstract]   [Full Text] [Related]  

  • 7. [-Increased AFP values-].
    Zimmermann R
    Arch Gynecol Obstet; 1995; 256 Suppl():S173-7. PubMed ID: 8619654
    [No Abstract]   [Full Text] [Related]  

  • 8. Maternal serum alpha-fetoprotein screening for Down syndrome: economic considerations.
    Swint JM; Greenberg F
    Am J Med Genet; 1988 Sep; 31(1):231-45. PubMed ID: 2464933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997.
    Egan JF; Benn P; Borgida AF; Rodis JF; Campbell WA; Vintzileos AM
    Obstet Gynecol; 2000 Dec; 96(6):979-85. PubMed ID: 11084189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comment on the contribution by Benz et al.: Serum screening for Down syndrome in women under 35 years of age with an age independent index].
    Reynolds T; Pistorius K; Spencer K; John R
    Z Geburtshilfe Neonatol; 1995; 199(3):128-9. PubMed ID: 7553259
    [No Abstract]   [Full Text] [Related]  

  • 12. Combining maternal age and serum alpha-fetoprotein to predict the risk of Down syndrome.
    Hershey DW; Crandall BF; Perdue S
    Obstet Gynecol; 1986 Aug; 68(2):177-80. PubMed ID: 2426637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal serum alpha-fetoprotein prenatal screening for Down syndrome.
    Boots LR; Davis RO; Foster JM; Goldenberg RL
    Ala Med; 1989 Jul; 59(1):25-7. PubMed ID: 2475015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum analysis in pregnant women. Mass screening is an effective way to discover chromosome aberrations--arguments for and against].
    Kristoffersson U; Nørgaard-Pedersen B
    Lakartidningen; 1995 Mar; 92(12):1205-6, 1211-2. PubMed ID: 7535873
    [No Abstract]   [Full Text] [Related]  

  • 15. First trimester maternal serum alpha-fetoprotein screening for Down syndrome and other aneuploidies.
    Wenger D; Miny P; Holzgreve W; Fuhrmann W; Altland K
    Am J Med Genet Suppl; 1990; 7():89-90. PubMed ID: 1705804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blood screening for Down's syndrome in women under 35 years of age with an age-independent index].
    Benz R; Müller U; Krahner-Pilat M; Wagner-Geuder S; Terinde R
    Z Geburtshilfe Perinatol; 1993; 197(5):205-8. PubMed ID: 7505992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counseling for low maternal serum alpha-fetoprotein should emphasize all chromosome anomalies, not just Down syndrome.
    Drugan A; Dvorin E; Koppitch FC; Greb A; Krivchenia EL; Evans MI
    Obstet Gynecol; 1989 Feb; 73(2):271-4. PubMed ID: 2463504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of normal MSAFP screening on maternal age for genetic amniocentesis.
    Ganiats TG; Berry CC; Fullerton JT
    J Clin Epidemiol; 1990; 43(11):1143-8. PubMed ID: 1700812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Down syndrome: the Jerusalem experience.
    Bach G; Ben-Neriah Z; Sagi M
    Isr J Med Sci; 1993 Aug; 29(8):468-70. PubMed ID: 7691779
    [No Abstract]   [Full Text] [Related]  

  • 20. Low MSAFP and new biochemical markers for Down syndrome: implications for genetic counselors.
    Kloza EM
    Birth Defects Orig Artic Ser; 1990; 26(3):31-43. PubMed ID: 1709365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.